

5 August 2025

Share Buyback Programme

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, announces that it intends to undertake a share buyback programme to return 500 million to shareholders, while maintaining leverage, and without compromising growth plans.

This additional return of value will be undertaken in the second half of 2025 and reflects strong cash generation and balance sheet resulting from the 12-Point Plan transformation. Further details are contained in Smith+Nephew's Second Quarter and First Half 2025 Results announcement published today, 5 August 2025.

To implement the buyback programme, Smith+Nephew has entered into a non-discretionary agreement with J.P. Morgan Securities plc in relation to the latter's purchase, acting as riskless principal, of the Company's ordinary shares of USD 0.20 each for an aggregate price of up to USD 500 million as part of the programme.

Shares acquired by J.P. Morgan Securities will be subsequently repurchased by Smith+Nephew, held as treasury shares and then either be cancelled or retained for the purpose of satisfying awards under employee share plans. The Programme will commence on 5 August 2025 and will end no later than 31 December 2025. The purpose of the Programme is to reduce Smith+Nephew's issued share capital by returning surplus capital to shareholders.

Any purchase of shares contemplated by this announcement will be carried out on Recognised Investment Exchanges^[1] and will be effected with certain pre-set parameters. The maximum number of ordinary shares which may be purchased by the Company is 87,440,566 ordinary shares, which is the maximum pursuant to the authority granted by shareholders at the Company's 2025 Annual General Meeting.

The programme will be executed in accordance with (and subject to the existence of and/or the limits prescribed by) the general authority granted by shareholders at the Company's relevant Annual General Meeting; and will be conducted within the parameters prescribed by the Market Abuse Regulation 596/2014/EU as it forms part of domestic law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (as amended) and Chapter 9 of the Financial Conduct Authority's UK Listing Rules. No repurchases will be made in respect of the Company's American Depositary Receipts.

J.P. Morgan Securities plc may undertake transactions in Shares (which may include sales and hedging activities, in addition to purchases which may take place on any available trading venue or on an over the counter basis) during the period of the Programme in order to manage its market exposure under the Programme. Disclosure of such transactions will not be made by J.P. Morgan Securities plc as a result of or as part of the Programme, but J.P. Morgan Securities plc will continue to make any disclosures it is otherwise legally required to make.

Smith+Nephew will make further announcements in due course following any repurchase of shares. There is no guarantee that the programme will be implemented in full or that any shares will be bought back by the Company.

Enquiries:

Investors

Cora McCallum +44 (0) 1923 477433
Smith+Nephew

Media

Charles Reynolds +44 (0) 1923 477314
Smith+Nephew

LEI: 213800ZTMDN8S67S1H61

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries and generated annual sales of 5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE 100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew'

2024. Smith+Nephew is a constituent of the FTSE 100 (Euronext, FTSE 100). The terms Group and Smith+Nephew are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on [X](#), [LinkedIn](#), [Instagram](#) or [Facebook](#).

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www.sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

◇ Trademark of Smith+Nephew. Certain marks are registered with the US Patent and Trademark Office.

[11] Note: Includes the London Stock Exchange, CBOE Europe Limited and Turquoise and Aquis Stock Exchange.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCUSAKRVNUWRAR